Chih-Ling Kuo

Title: Chih-Ling Kuo: Innovator in Cancer Therapy

Introduction

Chih-Ling Kuo is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer therapy through his innovative research and patented methods. His work focuses on improving treatment outcomes for cancer patients by utilizing plasma arginine levels.

Latest Patents

Chih-Ling Kuo holds a patent for "Methods for predicting response to arginine deprivation therapy based on plasma arginine levels in cancer patients." This method provides a prediction regarding whether a cancer patient will benefit from arginine deprivation therapy. The process involves determining the plasma level of arginine in the subject and subsequently administering arginine deprivation therapy, either alone or in combination with an anti-cancer agent, based on the determined plasma level. The anti-cancer agents may include FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, or combinations thereof.

Career Highlights

Kuo's career is marked by his dedication to advancing cancer treatment methodologies. His innovative approach to utilizing plasma arginine levels has the potential to enhance the effectiveness of cancer therapies, thereby improving patient outcomes. He is currently associated with Polaris Pharmaceuticals, Inc., where he continues to contribute to groundbreaking research in the field.

Collaborations

Chih-Ling Kuo collaborates with esteemed colleagues, including Hung-Wen Chen and Shaw Tsen Chen. Their collective expertise fosters an environment of innovation and progress in cancer research.

Conclusion

Chih-Ling Kuo's work exemplifies the intersection of innovation and healthcare, particularly in cancer therapy. His patented methods offer promising avenues for improving treatment responses in cancer patients. His contributions are vital to the ongoing efforts to enhance cancer care and patient outcomes.